| Heather D Driessen, DPM | |
|
1730 Saint Julian Pl, Columbia, SC 29204-2410 | |
| (803) 256-6776 | |
| (803) 256-6778 |
| Full Name | Heather D Driessen |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 16 Years |
| Location | 1730 Saint Julian Pl, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568602589 | NPI | - | NPPES |
| 003112634B | Medicaid | GA | |
| 003112634C | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | 625 (South Carolina) | Primary |
| 213ES0131X | Podiatrist - Foot Surgery | POD001173 (Georgia) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aiken Regional Medical Center | Aiken, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians Footcare, Llc | 4587748652 | 23 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
March 27 will be the day for two hours of arguments over the provision, which starting in 2014 will require most Americans to carry health insurance or pay a penalty. The high court is expected to announce its decision by the end of June.
A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
› Verified 5 days ago
| Provider Name | Physicians Footcare, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1194909556 PECOS PAC ID: 4587748652 Enrollment ID: O20080227000800 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
March 27 will be the day for two hours of arguments over the provision, which starting in 2014 will require most Americans to carry health insurance or pay a penalty. The high court is expected to announce its decision by the end of June.
A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
› Verified 5 days ago
| Provider Name | Emad Youssef Dpm Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1194331132 PECOS PAC ID: 8224457502 Enrollment ID: O20201006002371 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
March 27 will be the day for two hours of arguments over the provision, which starting in 2014 will require most Americans to carry health insurance or pay a penalty. The high court is expected to announce its decision by the end of June.
A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather D Driessen, DPM 1730 Saint Julian Pl, Columbia, SC 29204-2410 Ph: (803) 256-6776 | Heather D Driessen, DPM 1730 Saint Julian Pl, Columbia, SC 29204-2410 Ph: (803) 256-6776 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
March 27 will be the day for two hours of arguments over the provision, which starting in 2014 will require most Americans to carry health insurance or pay a penalty. The high court is expected to announce its decision by the end of June.
A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
› Verified 5 days ago
Dr. Maureen Quinlan, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1730 Saint Julian Pl, Columbia, SC 29204 Phone: 803-256-6776 Fax: 803-256-6778 | |
Elgin Podiatry Institute, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 3 Richland Medical Park Dr, Suite 110, Columbia, SC 29203 Phone: 803-807-9388 Fax: 803-807-9391 | |
Dr. Carly Chapman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1516 Calhoun St, Columbia, SC 29201 Phone: 803-254-6114 Fax: 803-254-7674 | |
James A Suber, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 1516 Calhoun St, Columbia, SC 29201 Phone: 803-254-6114 Fax: 803-254-7674 | |
Carolina Family Podiatry,llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 131 Wildewood Park Dr, Columbia, SC 29223 Phone: 803-462-7040 Fax: 803-462-7047 | |
Thomas A F Pinner, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2200 Harden St, Columbia, SC 29203 Phone: 803-898-8405 Fax: 808-898-8526 | |
Prisma Health Medical Group-midlands Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3 Richland Medical Park Dr Ste 350, Columbia, SC 29203 Phone: 803-434-6838 Fax: 803-434-6878 |